Learn more about our state-of-the-art biosimilar facility



Who we are

Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal: to be a global leader in the biosimilar space.

Read more

Research and development


We are focused on developing and bringing to market highest quality biosimilars. Our pipeline consists of six biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases. 

Read more


Generics bulletin casts spotlight on Alvotech

The latest issue of Generics bulletin, an international trade magazine, which covers news in the global generic medicines and biosimilars markets with subscribers in over 60 countries, features an in-depth article on Alvotech’s new state-of-the-art facility in Reykjavik. 

Read More

Meet management

World Class team

Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. The leadership team is helmed by Eef Schimmelpennink.

Leadership team


Partnering with Alvotech is gaining access to high quality, ready to market biosimilars


Meet us at .
Please tell us a little about yourself.

Meet Us